glp 1 cardiovascular risk and mortality outcomes with GLP-1 receptor agonists vs other glucose-lowering drugs in individuals with NAFLD and type 2 diabetes: a large population-based matched cohort study | Diabetologia Summary of large cardiovascular outcomes

Telling us about your GLP-1 medication does not make you difficultit makes you a well-informed partner in your own safety

Additionally, Li reiterates that these results appear independent of glycemic control, as their study population excluded type II diabetics entirely

GLP-1 receptor agonists slow gastric emptying and reduce appetite, which may decrease overall nutrient intake in some individuals

Microdosing is taking much smaller amounts than the standard starting dose, sometimes just a fraction

Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal-fat accumulation: a randomized clinical trial